SUBSCRIBE
SUBSCRIBE

Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.

With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.

For more information, please visit: www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.

  • 2025 BPTW Badge - RBG.png
  • 2024 - Best Places to Work - Badges - Brighspot Rework - Outlined - 20pt.png
211 Mt. Airy Road
Basking Ridge, NJ 07920
Tel: (908) 992-6400
Visit website
  • Featured Employer
NEWS
A scientist with pill bottles in front of FDA headquarters
Regulatory
FDA Action Alert: Ionis, Lexicon, Bristol Myers Squibb and More
The FDA’s year-end rush includes nine target action dates, mostly for rare disease and cancer therapies.
December 9, 2024
 · 
7 min read
 · 
Tristan Manalac
Pictured: Office building science collage
Career Advice
The Top 12 Companies Hiring in Biopharma Now
Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
December 5, 2024
 · 
1 min read
 · 
Angela Gabriel
Businessman holding a dart aiming at the target - business targeting, aiming, focus concept. Art collage.
Cancer
AstraZeneca/Daiichi Sankyo, BioNTech, Merus to Present Promising Cancer Therapies at ESMO Asia 2024
At the conference, AstraZeneca and Daiichi Sankyo will present their case for Dato-DXd in NSCLC, while BioNTech and Merus will reveal promising mid-stage data for their respective cancer candidates.
December 2, 2024
 · 
4 min read
 · 
Tristan Manalac
Illustration of hand holding trophy with people coming out of trophy and celebrating
Job Trends
BioSpace Announces 2025 Best Places to Work in Biopharma
BioSpace has named 50 biopharma companies to its 2025 Best Places to Work list, including Moderna and Sutro Biopharma, whose executives share what makes their organizations special.
November 12, 2024
 · 
6 min read
 · 
Angela Gabriel
3D illustration of an antibody-drug conjugate
Antibody-drug conjugate (ADC)
AstraZeneca, Daiichi Sankyo’s ADC Flops in Phase III Breast Cancer on Heels of Lung Cancer Stumble
Monday’s failure to improve overall survival in breast cancer “further dents belief” in the companies’ Dato-DXd and “likely complicates regulatory discussions for approval of this indication,” Jefferies analyst Peter Welford wrote in a note to investors.
September 23, 2024
 · 
3 min read
 · 
Tristan Manalac
Tumor microenvironment concept with cancer cells, T-Cells, nanoparticles, cancer associated fibroblast layer of tumor microenvironment normal cells, molecules, and blood vessels 3d rendering
Cancer
ADCs, Bispecifics and Radiopharma Take Center Stage at ESMO24
The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer treatment—antibody-drug conjugates, bispecifics and radiopharmaceuticals—while anti-TIGIT therapies made a bit of a comeback.
September 20, 2024
 · 
3 min read
 · 
Greg Slabodkin
3D illustration of an antibody-drug conjugate
Antibody-drug conjugate (ADC)
Merck, Daiichi Score Late-Stage NSCLC Win for ADC, Flag Two Deaths
Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental antibody-drug conjugate died in a Phase III non-small cell lung cancer study, though the deaths have not been linked to patritumab deruxtecan.
September 17, 2024
 · 
2 min read
 · 
Tristan Manalac
Antibody drug conjugates (ADCs) are targeted medicines that deliver chemotherapy agents to cancer cells 3d rendering
Antibody-drug conjugate (ADC)
AstraZeneca, Daiichi Sankyo’s Dato-DXd Fails to Significantly Improve Overall Survival in Phase III NSCLC
Despite the disappointing late-stage results in non-small cell lung cancer, Jefferies analyst Stephen Barker contends the likelihood of FDA approval “remains high” for the experimental antibody-drug conjugate, though the regulator is now more likely to convene an advisory committee.
September 10, 2024
 · 
2 min read
 · 
Tristan Manalac
Facade of AstraZeneca's office in Shanghai, China
Antibody-drug conjugate (ADC)
AstraZeneca, Daiichi Sankyo Turn to AI to Explain Phase III NSCLC Miss for Dato-DXd
Using a computational biomarker, the companies say they can identify which patients would derive significant clinical benefit from their experimental antibody-drug conjugate. AstraZeneca and Roche are co-developing and commercializing a companion diagnostic for the biomarker.
September 9, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
JOBS
View All Jobs at Daiichi Sankyo
IN THE PRESS
Press Releases
QuANTUM-Wild Phase 3 Trial of VANFLYTA® Initiated in Patients with Newly Diagnosed FLT3-ITD Negative AML
December 11, 2024
 · 
15 min read
Press Releases
Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
December 9, 2024
 · 
10 min read
Press Releases
Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
December 9, 2024
 · 
9 min read
Press Releases
Datopotamab Deruxtecan Demonstrated Meaningful Clinical Activity in Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer in TROPION-Lung05 and TROPION-Lung01 Pooled Analysis
December 6, 2024
 · 
11 min read
Press Releases
Daiichi Sankyo Highlights Progress Across Oncology Portfolio in Multiple Solid and Blood Cancers at ESMO Asia, SABCS and ASH
December 2, 2024
 · 
16 min read
Press Releases
GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
November 19, 2024
 · 
5 min read
Press Releases
Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOS
November 13, 2024
 · 
10 min read
Press Releases
Datopotamab Deruxtecan New BLA Submitted for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
November 12, 2024
 · 
10 min read
Press Releases
ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product
November 8, 2024
 · 
19 min read
Press Releases
Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
October 30, 2024
 · 
11 min read
Load More